Lack of HLA Class I Antigen Expression by Melanoma Cells SK-MEL-33 Caused by a Reading Frameshift in Beta 2-microglobulin Messenger RNA
Overview
Authors
Affiliations
The lack of HLA class I antigen expression by the melanoma cell line SK-MEL-33 is caused by a unique lesion in beta 2-microglobulin (beta 2-mu). Sequencing of beta 2-mu mRNA detected a guanosine deletion at position 323 in codon 76 that causes a frameshift with a subsequent introduction of a stop codon at a position 54 base upstream of the normal position of the stop codon in the message. The loss of 18 amino acids and the change of 6 amino acids, including a cysteine at position 80 in the carboxy terminus of beta 2-mu, are likely to cause marked changes in the structure of the polypeptide. The latter may account for the inability of beta 2-mu to associate with HLA class I heavy chains and for its lack of reactivity with the anti-beta 2-mu mAb tested. HLA class I antigen expression on SK-MEL-33 cells was reconstituted after transfection with a wild-type B2m gene, therefore indicating that the abnormality of endogenous B2m gene is the only mechanism underlying lack of HLA class I antigen expression by SK-MEL-33 cells. The guanosine deletion in B2m gene was detected also in the melanoma tissue from which SK-MEL-33 cells had originated. Therefore, the molecular lesion identified in the SK-MEL-33 melanoma cell line is not caused by a mutation acquired during growth in vitro but is likely to reflect a somatic mutation during tumor progression.
Minoura H, Okamoto R, Hiki N, Yamashita K Cancers (Basel). 2025; 17(5).
PMID: 40075643 PMC: 11899367. DOI: 10.3390/cancers17050795.
The immune-related role of beta-2-microglobulin in melanoma.
Wang C, Wang Z, Yao T, Zhou J, Wang Z Front Oncol. 2022; 12:944722.
PMID: 36046045 PMC: 9421255. DOI: 10.3389/fonc.2022.944722.
Cancer stem cells and macrophages: molecular connections and future perspectives against cancer.
Aramini B, Masciale V, Grisendi G, Banchelli F, DAmico R, Maiorana A Oncotarget. 2021; 12(3):230-250.
PMID: 33613850 PMC: 7869576. DOI: 10.18632/oncotarget.27870.
Prostate cancer health disparities: An immuno-biological perspective.
Kumar S, Singh R, Malik S, Manne U, Mishra M Cancer Lett. 2017; 414:153-165.
PMID: 29154974 PMC: 5743619. DOI: 10.1016/j.canlet.2017.11.011.
Guerrero A, Moyes J, Cooper L Chin J Cancer. 2014; 33(9):421-33.
PMID: 25189715 PMC: 4190432. DOI: 10.5732/cjc.014.10100.